Aurinia Pharmaceuticals Inc. (AUPH) Trading Up 8.2%
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were up 8.2% during trading on Friday . The company traded as high as $2.15 and last traded at $2.11, with a volume of 1,404,733 shares trading hands. The stock had previously closed at $1.95.
A number of research analysts have issued reports on the company. Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Canaccord Genuity reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, May 12th. HC Wainwright assumed coverage on Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They issued a “buy” rating and a $7.00 target price on the stock. Leerink Swann restated an “outperform” rating and issued a $7.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. Finally, FBR & Co reiterated an “outperform” rating and set a $9.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, August 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $7.75.
The firm’s market capitalization is $72.34 million. The stock’s 50-day moving average price is $2.87 and its 200 day moving average price is $2.76.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.